George Yancopoulos (L) and Len Schleifer (Regeneron)
January 5, 2021 10:57 AM EST
People

Re­gen­eron's Schleifer, Yan­copou­los set their com­pa­ny's am­bi­tions sky high with $1.4B on the ta­ble in per­for­mance awards

Kyle Blankenship

One of the true suc­cess sto­ries in bio­phar­ma, New York’s Re­gen­eron has built a $51 bil­lion mar­ket cap un­der the watch­ful eyes of co-founders and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times